Hyperprolinemia

Hyperprolinemia is an excess of a particular protein building block (amino acid), called proline, in the blood. This condition generally occurs when proline is not broken down properly by the body. There are two inherited forms of hyperprolinemia, called type I and type II.

People with hyperprolinemia type I often do not show any symptoms, although they have proline levels in their blood between 3 and 10 times the normal level. Some individuals with hyperprolinemia type I exhibit seizures, intellectual disability, or other neurological or psychiatric problems.

Hyperprolinemia type II results in proline levels in the blood between 10 and 15 times higher than normal, and high levels of a related compound called pyrroline-5-carboxylate. This form of the disorder has signs and symptoms that vary in severity, and is more likely than type I to involve seizures or intellectual disability.

Hyperprolinemia can also occur with other conditions, such as malnutrition or liver disease. In particular, individuals with conditions that cause elevated levels of lactic acid in the blood (lactic acidemia) may have hyperprolinemia as well, because lactic acid inhibits the breakdown of proline.

Frequency

It is difficult to determine the prevalence of hyperprolinemia type I because most people with the condition do not have any symptoms. Hyperprolinemia type II is a rare condition; its prevalence is also unknown.

Causes

Mutations in the ALDH4A1 and PRODH genes cause hyperprolinemia.

Inherited hyperprolinemia is caused by deficiencies in the enzymes that break down (degrade) proline. Hyperprolinemia type I is caused by a mutation in the PRODH gene, which provides instructions for producing the enzyme proline oxidase. This enzyme begins the process of degrading proline by starting the reaction that converts it to pyrroline-5-carboxylate.

Hyperprolinemia type II is caused by a mutation in the ALDH4A1 gene, which provides instructions for producing the enzyme pyrroline-5-carboxylate dehydrogenase. This enzyme helps to break down the pyrroline-5-carboxylate produced in the previous reaction, converting it to the amino acid glutamate. The conversion between proline and glutamate, and the reverse reaction controlled by different enzymes, are important in maintaining a supply of the amino acids needed for protein production, and for energy transfer within the cell.
A deficiency of either proline oxidase or pyrroline-5-carboxylate dehydrogenase results in a buildup of proline in the body. A deficiency of the latter enzyme leads to higher levels of proline and a buildup of the intermediate breakdown product pyrroline-5-carboxylate, causing the signs and symptoms of hyperprolinemia type II.

Inheritance Pattern

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. Most often, the parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but do not show signs and symptoms of the condition. In about one-third of cases, individuals carrying one copy of an altered PRODH gene have moderately elevated levels of proline in their blood, but these levels do not cause any health problems. Individuals with one altered ALDH4A1 gene have normal levels of proline in their blood.

Other Names for This Condition

- proline oxidase deficiency
- prolinemia
- pyrroline-5-carboxylate dehydrogenase deficiency
- pyrroline carboxylate dehydrogenase deficiency

Diagnosis & Management

Genetic Testing Information

- What is genetic testing?
  /primer/testing/genetictesting

- Genetic Testing Registry: Deficiency of pyrroline-5-carboxylate reductase

- Genetic Testing Registry: Proline dehydrogenase deficiency

Research Studies from ClinicalTrials.gov

- ClinicalTrials.gov
  https://clinicaltrials.gov/ct2/results?cond=%22hyperprolinemia%22

Other Diagnosis and Management Resources

- Baby's First Test
  https://www.babysfirsttest.org/newborn-screening/conditions/prolinemia
Additional Information & Resources

Health Information from MedlinePlus
• Health Topic: Amino Acid Metabolism Disorders
  https://medlineplus.gov/aminoacidmetabolismdisorders.html
• Health Topic: Genetic Brain Disorders
  https://medlineplus.gov/geneticbraindisorders.html
• Health Topic: Newborn Screening
  https://medlineplus.gov/newbornscreening.html

Genetic and Rare Diseases Information Center
• Hyperprolinemia type 2

Educational Resources
• MalaCards: hyperprolinemia
  https://www.malacards.org/card/hyperprolinemia
• Orphanet: Hyperprolinemia type 1
  https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=419
• Orphanet: Hyperprolinemia type 2
  https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=79101
• Screening, Technology and Research in Genetics
  https://www.newbornscreening.info/

Patient Support and Advocacy Resources
• Metabolic Support UK
  https://www.metabolicsupportuk.org/
• National Organization for Rare Disorders (NORD)
  https://rarediseases.org/rare-diseases/hyperprolinemia-type-i/
• National Organization for Rare Disorders: Hyperprolinemia Type II
  https://rarediseases.org/rare-diseases/hyperprolinemia-type-ii/

Scientific Articles on PubMed
• PubMed
  https://www.ncbi.nlm.nih.gov/pubmed?term=%28hyperprolinemia%5BTIAB%5D%29+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+3600+days%22%5Bdp%5D
Catalog of Genes and Diseases from OMIM

- HYPERPROLINEMIA, TYPE I
  http://omim.org/entry/239500
- HYPERPROLINEMIA, TYPE II
  http://omim.org/entry/239510

Sources for This Summary

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/9385373

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/9700195

- OMIM: HYPERPROLINEMIA, TYPE I
  http://omim.org/entry/239500
- OMIM: HYPERPROLINEMIA, TYPE II
  http://omim.org/entry/239510

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11510941

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12525555
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1735267/

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/10957843

Reprinted from Genetics Home Reference:

Reviewed: June 2007
Published: June 23, 2020

Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
National Institutes of Health
Department of Health & Human Services